Why the study?
Heart failure predisposes to thromboembolic events, but no guidance exists on the long-term use of anticoagulants for patients with heart failure in sinus rhythm.
Key points are not available for this paper at this time.
Population
Patients with HF in sinus rhythm
Design
Critical appraisal of a systematic review
Answers are grounded in this paper and cite their sources.
No mortality benefit in HF sinus rhythm supports withholding routine anticoagulation; reinforces lack of guidance and need for targeted trials.
One to two percent of the population in developed countries are affected by chronic heart failure and this increases to greater than 10% in those over 70 years old. Heart failure (HF) predisposes patients to thromboembolic events. Anticoagulants are often used to prevent thromboembolic events in specific patient populations, such as those with atrial fibrillation. Currently, no guidance exists on the long-term use of anticoagulants for patients with HF in sinus rhythm. This article critically appraises a systematic review which assesses whether the long-term use of oral anticoagulants reduces total mortality and stroke in patients with HF in sinus rhythm.
No takes yet. Share an insight, caveat, or question.
Hamer et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: